GlassScriptPhysician profile
Thomas H Merrill
NPI 1760474605
$774.11
in general payments reported to CMS, 2019-2025
18 companies · $293 in 2025
The $293 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $18.30 · 2020: $136 · 2023: $148 · 2024: $179 · 2025: $293.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $620.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $620.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $147.94 | 2023-2025 | |
| Musculoskeletal Transplant Foundation INC. | $135.78 | 2020 | |
| Glaxosmithkline, LLC. | $83.96 | 2023-2025 | Shingrix, Arexvy |
| Sanofi Pasteur INC. | $58.27 | 2024-2025 | |
| Vanda Pharmaceuticals INC. | $52.51 | 2024-2025 | Fanapt |
| Astellas Pharma US INC | $49.48 | 2024 | Veozah |
| Almatica Pharma LLC | $45.57 | 2025 | Teriparatide |
| Boston Scientific Corporation | $25.30 | 2025 | Watchman Access System |
| Sumitomo Pharma America, INC. | $23.68 | 2025 | Gemtesa |
| Xeris Pharmaceuticals, INC. | $23.09 | 2023 | Gvoke Hypopen |
| Dynavax Technologies Corporation | $19.34 | 2024 | Heplisav-B |
| Sunovion Pharmaceuticals INC. | $18.30 | 2019 | |
| Ge Healthcare | $17.22 | 2023 | |
| Amneal Pharmaceuticals LLC | $15.48 | 2025 | Unithroid |
| Amgen INC. | $14.96 | 2025 | Otezla, Repatha |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $14.69 | 2025 | Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.35 | 2025 | Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.19 | 2024 | Xifaxan |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Merrill listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.